PriceTargets.com logo

NASDAQ:AKRO - Akero Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.67
  • Forecasted Upside: 331.06 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$10.13 As of 07/5/2022 12:09 PM ET
▼ -0.02 (-0.20%)

This chart shows the closing price for AKRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akero Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKRO

Analyst Price Target is $43.67
▲ +331.06% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Akero Therapeutics in the last 3 months. The average price target is $43.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 331.06% upside from the last price of $10.13.

This chart shows the closing price for AKRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Akero Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/10/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2021Morgan StanleyBoost Price TargetEqual Weight$27.00 ➝ $29.00High
11/15/2021HC WainwrightLower Price TargetBuy$64.00 ➝ $62.00High
10/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$27.00Low
9/10/2021Bank of AmericaInitiated CoverageBuy$40.00Low
8/16/2021HC WainwrightLower Price TargetBuy$68.00 ➝ $64.00Low
3/23/2021Jefferies Financial GroupReiterated RatingBuy$48.00High
3/23/2021Morgan StanleyLower Price TargetOverweight$70.00 ➝ $63.00High
3/23/2021HC WainwrightBoost Price TargetPositive ➝ Buy$61.00 ➝ $68.00High
3/17/2021HC WainwrightLower Price TargetBuy$64.00 ➝ $61.00High
3/17/2021Chardan CapitalBoost Price TargetPositive ➝ Buy$79.00 ➝ $81.00High
2/26/2021GuggenheimInitiated CoverageBuy$54.00Low
11/13/2020HC WainwrightBoost Price TargetBuy$62.00 ➝ $64.00High
9/10/2020Morgan StanleyInitiated CoverageOverweight$70.00High
8/13/2020Chardan CapitalReiterated RatingBuyLow
7/20/2020HC WainwrightBoost Price TargetBuy$45.00 ➝ $62.00High
7/7/2020Chardan CapitalInitiated CoverageBuy$79.00High
7/1/2020JPMorgan Chase & Co.Boost Price TargetOverweight$28.00 ➝ $41.00High
7/1/2020Jefferies Financial GroupBoost Price TargetBuy$31.00 ➝ $48.00High
7/1/2020HC WainwrightBoost Price TargetBuy$33.00 ➝ $45.00High
3/2/2020HC WainwrightInitiated CoverageBuy$33.00High
7/15/2019Evercore ISIInitiated CoverageOutperform ➝ Outperform$35.00Low
7/15/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$28.00High
7/15/2019Roth CapitalInitiated CoverageBuy ➝ Buy$34.00High
7/15/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$28.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2022

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Akero Therapeutics logo
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $10.13
Low: $9.95
High: $10.69

50 Day Range

MA: $9.62
Low: $8.00
High: $12.16

52 Week Range

Now: $10.13
Low: $7.52
High: $26.98

Volume

6,983 shs

Average Volume

565,542 shs

Market Capitalization

$354.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Akero Therapeutics?

The following Wall Street analysts have issued reports on Akero Therapeutics in the last twelve months: Bank of America Co., HC Wainwright, and Morgan Stanley.
View the latest analyst ratings for AKRO.

What is the current price target for Akero Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Akero Therapeutics in the last year. Their average twelve-month price target is $43.67, suggesting a possible upside of 331.1%.
View the latest price targets for AKRO.

What is the current consensus analyst rating for Akero Therapeutics?

Akero Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AKRO will outperform the market and that investors should add to their positions of Akero Therapeutics.
View the latest ratings for AKRO.

How do I contact Akero Therapeutics' investor relations team?

Akero Therapeutics' physical mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 487-6488 and its investor relations email address is [email protected] The official website for Akero Therapeutics is www.akerotx.com. Learn More about contacing Akero Therapeutics investor relations.